| Drug General Information |
| Drug ID |
D0F0ZY
|
| Former ID |
DAP001550
|
| Drug Name |
Pazopanib HCl
|
| Synonyms |
Votrient (TN)
|
| Drug Type |
Small molecular drug
|
| Indication |
Renal cancer [ICD9: 140-229, 189; ICD10:C64]
|
Approved |
[1]
|
|---|
| Company |
GlaxoSmithKline
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C21H24ClN7O2S
|
| Canonical SMILES |
CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)<br />C)S(=O)(=O)N.Cl
|
| InChI |
1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
|
| InChIKey |
MQHIQUBXFFAOMK-UHFFFAOYSA-N
|
| CAS Number |
CAS 444731-52-6
|
| PubChem Compound ID |
|
| SuperDrug ATC ID |
L01XE11
|
| Target and Pathway |
| Target(s) |
Platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
| Mast/stem cell growth factor receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
|
Hematopoietic cell lineage
|
|
Melanogenesis
|
|
Pathways in cancer
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_15:IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
KitReceptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkcmyb_pathway:C-MYB transcription factor network
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP304:Kit receptor signaling pathway
|
|
Differentiation Pathway
|
|
Signaling by SCF-KIT
|
|
PIP3 activates AKT signaling
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
| References |
| REF 1 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. |
|---|
